Jaguar Health, Inc. (JAGX) Form 10-Q — Nov 16, 2026
Jaguar Health filed its Q3 2026 10-Q reporting $23.8 million in nine-month revenue, up sharply from $8.3 million a year ago, driven almost entirely by $20.8 million of license and supply revenue from the Woodward Specialty agreement covering Mytesi and Canalevia-CA1. Net loss narrowed to $9.9 million from $30.8 million. The filing contains substantial-doubt going-concern language: the company holds just $5.5 million in cash against an accumulated deficit of $409.5 million, and management concedes current resources are insufficient to fund operations for one year. Woodward alone accounts for 98% of revenue, creating extreme customer concentration.
Key figures
- Revenue
- 23840000
- Total Debt
- 2493000
- Total Assets
- 32511000
- Cash Position
- 5528000
- Shares Outstanding
- 13345986
- Q3 revenue
- 2343000
- Q3 net loss
- 5830000
- Going concern
- Yes
- Reverse splits
- 1-for-35 (April 30, 2026) and 1-for-15 (September 17, 2026)
- Accumulated deficit
- 409500000
- Woodward license revenue
- 20800000
- Woodward revenue concentration pct
- 98
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.